Abha Kundi*’s Insights

20 total results. Page 1 of 2.

Alerts
All Filler, No Foundation: Pure Indulgence’s 483 Becomes a DSCSA Warning Letter
Longevity Lens
The Brain-Computer Interface Race Is On – Is the Law Ready?
Events
2026 Chicago Pharma Forum
Alerts
Navigating the 2026 Life Sciences Legal Landscape
Alerts
NDSee You in 2033: FDA’s 12‑Digit NDC Is Coming
Health Care Counsel Blog
CMS ACCESS Model Update: Payment Rates and Performance Targets Released for 2026–2027
Longevity Lens
The Regulatory Roadmap: Five Critical Questions for Evaluating Regulatory Risk for Longevity Companies
Longevity Lens
The Eyes Have It: FDA Approves Phase 1 Clinical Trial of Life Biosciences’ Reprogramming Therapy for Vision Loss
Longevity Lens
ArentFox Schiff Launches First-of-Its-Kind Longevity & Healthspan Industry Group
Alerts
Model Behavior: FDA and EMA’s Guide to Good AI in Drug Development
Alerts
FDA Issues Updated Guidance on Low-Risk General Wellness Devices and Clinical Decision Support Software
Alerts
A Wrinkle in the Supply Chain: FDA’s First DSCSA 483 for a Dispenser